Nearly all of it is mild or moderate, and it has little to do with how much weight people lose. The nutrition advisory written for these medicines recommends a small breakfast, small meals every three to four hours, and less fat. Vomiting that lasts longer than 24 hours, or being unable to keep fluids down for 12 hours, needs medical care.1,2,5,6,7
How common nausea and vomiting are
Each label has a table of the reactions reported in its placebo-controlled trials. These are the rows for nausea and for vomiting.
| Medicine | Nausea: placebo, then doses | Vomiting: placebo, then doses |
|---|---|---|
| Wegovy, 68-week trials | 16%, then 44% on 2.4 mg | 6%, then 24% on 2.4 mg |
| Wegovy, 72-week trials of the higher dose | 13%, then 35% on 2.4 mg, 39% on 7.2 mg | 6%, then 16% on 2.4 mg, 22% on 7.2 mg |
| Zepbound 5, 10, 15 mg | 8%, then 25%, 29%, 28% | 2%, then 8%, 11%, 13% |
| Mounjaro 5, 10, 15 mg | 4%, then 12%, 15%, 18% | 2%, then 5%, 6%, 9% |
| Ozempic 0.5, 1 mg | 6.1%, then 15.8%, 20.3% | 2.3%, then 5%, 9.2% |
Prescribing information for Wegovy, Zepbound, Mounjaro and Ozempic, section 6.1.1,2,3,4
The percentages count people who reported the reaction at least once during the trial, mild reports included. Compare each medicine with its own placebo group; the trials enrolled different people.
A word on what these percentages are. Each one is the share of people who reported nausea at least once over a trial that lasted more than a year. It is not the share who feel sick in any given week. The pooled analysis described below tracked that second figure over time, and it rises to a peak and then falls.5
Three things stand out.
It rises with the dose. Unlike constipation or abdominal pain, nausea and vomiting are more frequent on the highest dose than on the lowest on every label: 18% against 12% on Mounjaro, 20.3% against 15.8% on Ozempic, and 39% on Wegovy 7.2 mg against 35% on 2.4 mg in the same trials. Zepbound is nearly level across its three doses for nausea, and climbs for vomiting, from 8% to 13%.1,2,3,4
The weight-management trials report more of it. Semaglutide gives 44% on Wegovy and 16% to 20% on Ozempic. Tirzepatide gives 25% to 29% on Zepbound and 12% to 18% on Mounjaro at the same doses. The placebo groups differ in the same direction, 8% to 16% against 4% to 6%, so part of the gap comes from who was in the trials and how long they ran.
Teenagers report vomiting more often. In the pediatric trial of Wegovy, nausea was reported by 42% on the drug and 18% on placebo, close to the adult figures, and vomiting by 36% against 10%.1
When it starts and when it fades
The fullest account of timing is a pooled analysis of three 68-week trials of Wegovy 2.4 mg, in which 43.9% of people on the drug and 16.1% on placebo reported nausea.5
- It starts during the dose steps. Among people who reported any stomach or gut event, the vast majority had their first one during the dose-escalation period, which on Wegovy is the first 16 weeks.
- It is most frequent at about week 20. The share of people with nausea at any one time peaked at about week 20 and decreased after that. Of the three short-lived reactions, nausea showed the most prominent decline.
- It does not vanish. The share with nausea stayed above the placebo level for the whole 68 weeks.
The other labels agree without giving weeks. On Zepbound and Mounjaro the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time, and on Ozempic the majority occurred during dose escalation.2,3,4 The nutrition advisory of four U.S. medical societies adds a detail about the time of day: nausea often occurs in the morning or after longer periods without eating.6
The steps are the earliest the label allows; a prescriber can hold a dose longer, and many people stay below the top dose. The calendar shows dates only and is not a dosing instruction.
Week by week on Wegovy
Putting the label's dose steps next to the pooled analysis gives a rough map of the first half-year on Wegovy.1,5
| Weeks | Weekly dose | What the trials showed |
|---|---|---|
| 1 to 4 | 0.25 mg | The starting dose. First episodes of nausea begin for many people during the dose steps. |
| 5 to 16 | 0.5 mg, then 1 mg, then 1.7 mg | A step every four weeks. Stomach reactions are most frequent during or shortly after each step. |
| 17 to 20 | 2.4 mg | The share of people with nausea reaches its highest point at about week 20. |
| After 20 | 2.4 mg | Nausea becomes less frequent, the most clearly of the three short-lived reactions, and stays above the placebo level. |
Wegovy prescribing information, section 2; Wharton 2022.1,5
The higher Wegovy dose adds a little more. In the 72-week trials, nausea was reported by 39% on 7.2 mg against 35% on 2.4 mg, and vomiting by 22% against 16%.1
How long one episode lasts
Short, by the same analysis. The median duration of an episode of nausea on Wegovy 2.4 mg was 8 days, and of vomiting 2 days. Both were similar to placebo: the drug made episodes more frequent and did not make each one longer.5 For comparison, an episode of diarrhea lasted a median of 3 days and one of constipation 47.
A median means half of the episodes were shorter and half were longer. The medians are for Wegovy 2.4 mg; no label or paper we opened reports the length of an episode on Zepbound, Mounjaro or Ozempic. A person can have more than one episode.
The days after a shot
The labels do not say on which day of the week nausea is worst. The one piece of timing they give is when the drug itself peaks in the blood. For semaglutide, the maximum concentration is reached 1 to 3 days after the dose. For tirzepatide, the Zepbound label gives a median of 24 hours, anywhere from 8 to 72 hours.1,2,3,4
The peak window is each label's. The curve comes from our model, built on the label half-lives, for a settled weekly dose; it is not a blood test. No source here ties nausea to the hour of the peak, so the window is a place to look in your own log and not a prediction.
If your own queasy days cluster inside that window, the advice in the sections below applies with most force there: smaller meals and less fat on those days in particular.
How bad it gets, and who stops
In the pooled Wegovy trials, 98.1% of all stomach and gut events were rated mild or moderate, and 99.5% were not serious. Reactions of this kind as a group ended treatment for 4.3% of people on the drug.5 The Wegovy label breaks that down: nausea was the reason for stopping in 1.8% of adults on the drug against 0.2% on placebo, and vomiting in 1.2% against none.1
The labels also count severe stomach and gut reactions of any kind: 4.1% of adults on the Wegovy injection against 0.9% on placebo, 1.7% to 3.1% on Zepbound against 1%, 0.4% to 1.3% on Mounjaro against 0.9%, and 0.4% to 0.8% on Ozempic against none.1,2,3,4
The other labels give the share who stopped because of any stomach or gut reaction: 1.9% to 4.3% on Zepbound against 0.5% on placebo, 3.0% to 6.6% on Mounjaro against 0.4%, and 3.1% to 3.8% on Ozempic against 0.4%.2,3,4 Put the two sets of numbers side by side and the picture is consistent: between 12% and 44% of people feel nauseated at some point, and a few in a hundred find it bad enough to quit.
Why a GLP-1 causes nausea
Two actions of these medicines bear on it, and the sources lean toward the first.
The brain. The Wegovy label describes the receptor for GLP-1 as present in several areas of the brain involved in appetite regulation, and says that in animal studies semaglutide reached and activated neurons in regions that regulate food intake.1 The nutrition advisory states that GLP-1 medicines activate several brain regions responsible for weight regulation, appetite and nausea.6 The authors of the pooled Wegovy analysis wrote that the mechanism of the nausea may primarily relate to central effects, citing animal studies in which the response involved GLP-1 receptors in the central nervous system.5
The stomach. All four labels state that the medicine delays the emptying of the stomach, and the advisory says that this delay leads to bloating, fullness and nausea.1,6 The delay is not constant, though. The Zepbound and Mounjaro labels say it is largest after the first dose and diminishes over time.2,4 A 20-week trial of semaglutide 2.4 mg found no evidence at week 20 that the stomach emptied more slowly than on placebo, measured by the absorption of paracetamol, while appetite stayed lower.9
That fits the shape of the timeline: most nausea early and around each dose step, when the delay in stomach emptying is largest, and less later even though the dose is higher.
Not hungry is not the same as nauseated
A lower appetite is the intended effect of these medicines, and it shows up in the same trials as a separate finding. In the 20-week trial of semaglutide 2.4 mg, people ate 35% less at a test lunch than on placebo.9 The Mounjaro label lists decreased appetite as its own reaction, reported by 5% on 5 mg, 10% on 10 mg and 11% on 15 mg, against 1% on placebo.4 The two feelings can blur, and the nutrition advisory describes how one feeds the other: people stop eating because of nausea, the empty stomach worsens the nausea, and eating becomes less likely still.6 Its remedy, small meals at regular intervals, is aimed at that loop.
Is nausea how the drug works?
No. The pooled analysis compared people on Wegovy who had stomach and gut events with those who had none. Weight lost by week 68 was nearly the same: 17.3% against 15.7% in the main trial, 11.4% against 9.6% in the trial in people with type 2 diabetes, and 17.7% against 17.1% in the trial with intensive lifestyle therapy. A mediation analysis in the same paper found that these events contributed little to the weight loss.5
This matters for two decisions. Someone who feels fine is not getting less from the medicine. And someone who is nauseated does not need to put up with it for the sake of the result, because the weight loss in the trials did not depend on having these reactions.
What helps: the advisory's plan
The fullest advice written for people on these medicines comes from a 2025 joint advisory of the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society.6 It is expert guidance and not the result of a trial of each step. Its points on nausea:
- Do not skip meals to avoid nausea. Some people get caught in a cycle of not eating because of nausea, which worsens the symptoms, which then makes eating even less likely.
- Start with a small breakfast. Then eat additional small meals every 3 to 4 hours, while drinking adequate fluids.
- Smaller, more frequent meals. Vomiting is more likely with large meals.
- Less fat and less fiber for the first few days after a dose. Avoiding fatty or high-fiber foods during the first few days of treatment can help.
- Ginger or peppermint tea, and acupressure bands, can be beneficial.
- Anti-nausea medicines can provide relief while a person adjusts and during dose increases.
The advisory also puts part of the work before the first dose. It says clinicians should present these side effects in detail before starting therapy, advise people to contact them early if side effects develop, and provide the steps above in advance.6 Someone who was not given such a plan can ask for one.
MedlinePlus, the medical encyclopedia of the U.S. National Library of Medicine, adds the simplest step for nausea from any cause: drink small amounts of clear liquids often.7
Log meals and queasy hours in the app and see whether the long gaps are the bad ones.
Open the appThe gap of 3 to 4 hours and the small breakfast are the advisory's. The last meal is placed at least 3 hours before bed, which is NIDDK's guidance for reflux at night (see our page on burping and reflux). The times are a sketch to adapt, not a prescription.
What "less fat" looks like on a plate
The advisory's advice to avoid fatty foods in the first days after a dose is easier to follow with numbers. These are the grams of fat in one portion of common foods, from the U.S. Department of Agriculture's food database.11
| Lower in fat | Fat g | Higher in fat | Fat g |
|---|---|---|---|
| White rice, ½ cup | 0.2 | French fries, medium serving | 17.2 |
| Banana, 1 medium | 0.4 | Peanut butter, 2 tbsp | 16.4 |
| Chicken broth, 1 cup | 0.5 | Beef patty, 3 oz | 15.1 |
| Greek yogurt, nonfat, 1 container | 0.7 | Almonds, 1 oz | 14.2 |
| Tuna in water, 3 oz | 0.7 | Olive oil, 1 tbsp | 13.5 |
| Saltine crackers, 5 | 1.3 | Avocado, ½ cup | 11.0 |
| Cottage cheese, 2%, 4 oz | 2.6 | Salmon, 3 oz | 10.5 |
| Chicken breast, ½ breast | 3.1 | Doughnut, 1 | 10.0 |
USDA FoodData Central, SR Legacy, per portion.11
The right-hand column is not a list of foods to give up. The point is narrower and concerns the few days when nausea is at its worst. Half a chicken breast with white rice and a cup of broth comes to 3.8 grams of fat. A beef patty with a medium serving of fries comes to 32.3.
Fluids
The advisory asks for adequate fluids alongside the small meals, and MedlinePlus for small amounts of clear liquids often.6,7 Small and often is the operative part when a full stomach is the problem. What each kind of drink replaces, cup by cup, is laid out on our page on diarrhea on a GLP-1.
Ginger, in more detail
Ginger is the remedy most often named, and it has been tested for several kinds of nausea. The National Center for Complementary and Integrative Health, part of the National Institutes of Health, summarizes the research this way: ginger may be helpful for nausea and vomiting associated with pregnancy; most studies for motion sickness have not shown it to be helpful; and it is uncertain whether it helps with nausea from chemotherapy or after surgery. Most studies tested supplements and not foods. Taken by mouth, ginger can cause abdominal discomfort, heartburn and diarrhea.8 No study in that summary concerns nausea from a GLP-1 medicine, and heartburn is already a reaction to these medicines, so ginger tea is a reasonable thing to try and not a proven one.
Anti-nausea medicines
The advisory makes one specific point about them. Agents such as prochlorperazine may be preferable to those that act on serotonin receptors, such as ondansetron, because the latter can worsen constipation, which is itself a common reaction to these medicines.6 NIDDK lists both among prescription medicines for nausea, so the choice is the prescriber's. It lists bismuth subsalicylate and diphenhydramine as over-the-counter medicines for nausea and notes that such medicines do not make the stomach empty faster.10 Doses are on the product label and are not given here.
Slowing the dose steps
Because nausea follows the dose, the schedule is the main lever, and the labels build flexibility into it. The Wegovy label says that if a patient does not tolerate a dose during escalation, the prescriber can consider delaying the next step for four weeks. The Zepbound label says to consider tolerability when selecting the maintenance dose, and a lower one if the current dose is not tolerated.1,2
The advisory describes how this was handled in the trials and in practice. During dose escalation in the clinical trials, participants were allowed to remain at a dose for up to 8 weeks, as needed, to let stomach side effects dissipate. Some of the advisory's authors go further in their own practice and keep people at the lowest effective dose, raising it only when weight reduction stops, although they note that shortages or insurance rules for lower doses can stand in the way.6
Both are decisions to make with the prescriber. What the evidence above adds is that the trade is a mild one, since weight loss in the trials did not depend on having these reactions.
When nausea turns into vomiting
Vomiting is less common than nausea and briefer, a median of 2 days per episode on Wegovy, but it is the reaction that removes fluid.5 All four labels carry a warning about acute kidney injury due to volume depletion, noting that the majority of reported events occurred in patients who had nausea, vomiting or diarrhea leading to dehydration.1,2,3,4 The advisory repeats the point and adds heart palpitations to the consequences of dehydration.6
MedlinePlus gives the thresholds. Call 911 or go to an emergency room if you notice blood or dark, coffee-colored material in the vomit. Contact your provider right away or seek medical care if you have:7
- been vomiting for longer than 24 hours;
- been unable to keep any fluids down for 12 hours or more;
- vomited 3 or more times in 1 day;
- not urinated for 8 or more hours;
- severe stomach or belly pain;
- headache or stiff neck.
Its signs of dehydration are a dry mouth, increased thirst, eyes that appear sunken, skin that does not bounce back when squeezed, and urinating less often or having dark yellow urine.7
The lists are from MedlinePlus and apply to nausea and vomiting from any cause. A page cannot examine you. If something feels seriously wrong, do not wait for it to agree.
If you take the medicine for diabetes
Ozempic and Mounjaro, the versions approved for type 2 diabetes, have lower rows than their weight-management twins: 15.8% to 20.3% and 12% to 18%, against 6.1% and 4% on placebo.3,4 One extra point applies. The labels warn that people who take these medicines together with insulin or a sulfonylurea may have an increased risk of low blood sugar, and that lowering the dose of the insulin or sulfonylurea may reduce it.3,4 Someone on that combination who is eating much less because of nausea, or vomiting meals, has a reason to tell the prescriber promptly.
When the nausea is not the injection
Between 4% and 16% of people on placebo reported nausea in these trials, so some of it during treatment has another cause. MedlinePlus lists the common ones: infections of the stomach or bowels, food poisoning, reflux, migraine, motion sickness, morning sickness during pregnancy, severe pain, and slow emptying of the stomach. Its list of medicines that cause nausea now includes this class by name, as glutides, a type of medicine used to treat diabetes or obesity.7
Three causes deserve attention on a GLP-1 in particular.
- The conditions the labels warn about. Nausea and vomiting with persistent or severe abdominal pain is how the labels describe pancreatitis, and the patient leaflets say to stop the medicine and call right away for severe stomach pain that will not go away. Nausea with pain in the upper right abdomen, fever or yellow skin points to the gallbladder.1 Our page on stomach pain on a GLP-1 covers both.
- A blockage. MedlinePlus lists a blockage in the intestines among the serious problems of which nausea and vomiting can be early warning signs.7 Our page on bowel obstruction and ileus lists the signs.
- Pregnancy. Morning sickness is on the list of common causes. The Wegovy label says to discontinue the medicine at least 2 months before a planned pregnancy, because semaglutide is cleared slowly.1 New nausea in someone who could be pregnant is a reason for a test and a call to the prescriber.
Short answers to common questions
How long does nausea last on a GLP-1?
One episode on Wegovy 2.4 mg lasted a median of 8 days, similar to placebo. Episodes were most frequent up to about week 20 and less frequent after that.
When does the nausea start?
Mostly during the dose steps. The labels of all four medicines say most nausea, vomiting and diarrhea came during dose escalation.
Which GLP-1 causes the least nausea?
The labels cannot answer that, because each drug was tested in different people against a different placebo group. Within each label, lower doses have less: 12% on Mounjaro 5 mg against 18% on 15 mg, and 15.8% on Ozempic 0.5 mg against 20.3% on 1 mg.
Does nausea mean the medicine is working?
No. In the Wegovy trials people without stomach reactions lost almost as much weight as people with them, 15.7% against 17.3% in the main trial.
What should I eat when I feel sick?
The nutrition advisory suggests a small breakfast, small meals every 3 to 4 hours, adequate fluids, and avoiding fatty or high-fiber foods for the first few days after a dose.
Does ginger help?
The advisory says ginger or peppermint tea can be beneficial. The NIH summary of ginger research finds evidence for pregnancy nausea and none specific to these medicines.
Can I take an anti-nausea medicine?
The advisory says they can provide relief during dose increases, and that prochlorperazine may be preferable to ondansetron because ondansetron can worsen constipation. That choice is the prescriber's.
When is the nausea worst after the shot?
The labels do not say. The drug itself peaks 1 to 3 days after a semaglutide dose and about 24 hours after a tirzepatide dose.
Does the time of day or the injection site change the nausea?
The labels do not say so. They allow the weekly dose at any time of day, with or without meals, and none of them links the time or the site of injection to nausea.
When should I call a doctor?
MedlinePlus says right away for vomiting longer than 24 hours, no fluids kept down for 12 hours, vomiting 3 or more times in a day, no urine for 8 hours, or severe belly pain.
How this page was built
Every number was read in its source on November 20, 2026. The rates come from the current prescribing information of the four medicines. The timing, length and severity of episodes and the comparison of weight loss come from a pooled analysis of the Wegovy trials, funded by the drug's maker. The practical advice comes from a 2025 joint advisory of four medical societies, which is expert opinion. The thresholds for seeking care come from the MedlinePlus entry on nausea and vomiting reviewed in July 2025, and the summary of ginger research from the NIH page updated in February 2025.
The limits are these. The length of an episode is known for Wegovy only. No source here tested any remedy for nausea in people taking a GLP-1, and none ties nausea to a day of the week or to the peak of the drug. The level curve is a model. The label rates count every report regardless of severity. This page does not suggest doses of any medicine.
Sources
- WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1, 8, 12 and 17. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1 and 12. accessdata.fda.gov
- OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1 and 12. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 2, 5, 6.1 and 12. accessdata.fda.gov
- Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi:10.1111/dom.14551
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
- MedlinePlus Medical Encyclopedia. Nausea and vomiting - adults. U.S. National Library of Medicine; reviewed July 22, 2025, read November 20, 2026. medlineplus.gov
- National Center for Complementary and Integrative Health. Ginger: Usefulness and Safety. Last updated February 2025, read November 20, 2026. nccih.nih.gov
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
- National Institute of Diabetes and Digestive and Kidney Diseases. Treatment for Gastroparesis. Last reviewed January 2018, read November 20, 2026. niddk.nih.gov
- U.S. Department of Agriculture, Agricultural Research Service. FoodData Central, SR Legacy (2018), read November 20, 2026; the entries for the 16 foods in the table. fdc.nal.usda.gov
Related analyses
Alcohol on a GLP-1: what the labels say, what counts as a drink, and what five studies found
Bowel obstruction and ileus on a GLP-1: six studies and four labels
Burping, reflux and gas on a GLP-1: how common, why, and what helps
Constipation on a GLP-1: how common, how long, and what the evidence says helps
Log each dose and each queasy day, and see whether they follow the dose steps.
Open Dose Insider